Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Plethora Solutions PLC was a United Kingdom-based specialty pharmaceutical company primarily focused on the development and commercialization of treatments for urological disorders, with a significant emphasis on premature ejaculation (PE). Its flagship product was PSD502, a topical spray for PE, marketed under names such as Fortacin® and Senstend® in Europe. Founded in 2003, the company was listed on the AIM market of the London Stock Exchange. In late 2015 to early 2016, Plethora Solutions was acquired by Regent Pacific Group Limited, and its operations and assets, including the rights to Fortacin®, were integrated into the acquiring company. Plethora Solutions PLC was subsequently dissolved.
Served as a key center for research and development, clinical trial management, and strategic planning for its pharmaceutical products, notably PSD502.
Located within The Surrey Research Park, a hub for technology and life science companies, offering access to specialized facilities and a collaborative environment. Specific internal features of Plethora's leased space are not publicly detailed.
As a pharmaceutical R&D company, the culture likely prioritized scientific innovation, meticulous research, regulatory compliance, and a focus on bringing novel treatments to patients. This would have involved collaboration among scientists, clinicians, and business development professionals.
This operational base was crucial for advancing Plethora's lead product through clinical development, regulatory approval processes, and preparing for commercialization in European markets.
Plethora Solutions' global presence was primarily driven by its efforts to secure regulatory approval and commercialize its lead product, Fortacin®/Senstend®, in Europe. While its operational core was in the UK, it established partnerships for distribution and marketing in various European countries post-product approval. It did not maintain a widespread network of international physical offices, instead leveraging licensing and distribution agreements to achieve market access outside the UK.
The Surrey Research Park (specific unit unconfirmed)
Guildford
Surrey
United Kingdom
Address: Chancery House, 19 Degree C St. Albans Road, Watford, WD17 1DU, United Kingdom (Historical Registered Office)
Fulfilled UK legal requirements for company registration and official communications.
Address: C/O Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES (Final Registered Office)
Served for final statutory requirements and legal processes during the company's dissolution.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Plethora Solutions' leadership includes:
Plethora Solutions has been backed by several prominent investors over the years, including:
Plethora Solutions PLC was acquired in 2015-2016 and subsequently dissolved. Therefore, there have been no executive new hires or exits for 'Plethora Solutions' as an independent entity in the last 12 months or for several years prior.
Discover the tools Plethora Solutions uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition and dissolution, Plethora Solutions likely used a standard corporate email format. Common formats included [first].[last]@[companydomain].co.uk or [first_initial][last]@[companydomain].co.uk. These email addresses are no longer active.
[first].[last]@plethorasolutions.co.uk
Format
john.smith@plethorasolutions.co.uk (Example, Inactive)
Example
0%
Success rate
Reuters • December 21, 2015
Regent Pacific Group announced a recommended all-share offer to acquire Plethora Solutions PLC. The deal valued Plethora at approximately £102.7 million and was aimed at securing the rights to Plethora's premature ejaculation treatment, Fortacin....more
Zenopa • November 14, 2013
Plethora Solutions announced that the European Commission had granted marketing authorisation for PSD502 (Fortacin™) for the treatment of premature ejaculation in the European Union, following a positive recommendation from the CHMP in September 2013....more
Pharmaceutical Technology • March 8, 2010
Plethora Solutions reported positive top-line results from its pivotal Phase III clinical trial for PSD502 (Tempe), its candidate treatment for premature ejaculation. The study met all primary and secondary endpoints, demonstrating a statistically significant improvement....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Plethora Solutions, are just a search away.